Trm with a regulatory signature have also been described to be reduced in IBD, characterized by CD103+Runx3+ and expression of the regulatory-associated molecules CD39 and CD73 together with IL-10 production (281). This evidence concerns the gene ITGAE and inflammatory bowel disease.